Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biejia-Ruangan plus entecavir for chronic hepatitis B-related liver fibrosis
ChiCTR1800018985Phase 4Not yet recruiting
- Sponsor
- 302 Hospital of the People's Liberation Army
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Fufang Biejia Ruangan and entecavir in Chronic Hepatitis B (CHB) and hepatic fibrosis (2 arms), sponsored by 302 Hospital of the People's Liberation Army. Primary endpoints: Liver histological changes and Clinical endpoint events. Planned start Oct 2018; status: not yet recruiting.
02
Drugs
Fufang Biejia Ruanganentecavir
03
Conditions
Chronic Hepatitis B (CHB)hepatic fibrosis
Beyond the preview
Go deeper on ChiCTR1800018985.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800018985.